Browsing Tag
Keytruda
47 posts
Merus N.V. stock soars on breakthrough cancer trial: What drove MRUS to the top gainers list?
Merus N.V. stock jumped 32% on breakthrough cancer trial data. Find out what’s driving MRUS and what could come next for this biotech leader.
Innovent begins IBI363 pivotal study in melanoma immunotherapy
Innovent Biologics, Inc. (HKEX: 01801), a global biopharmaceutical company specializing in innovative oncology therapies, has dosed the first…
Scientists investigate NPRL2 gene therapy for hard-to-treat lung cancer—What they found
A significant study published in eLife suggests that NPRL2 gene therapy could offer a new therapeutic approach for…
Hanmi Pharmaceutical, Beijing Hanmi progress cancer therapy BH3120 with promising trial results
Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical are making significant strides in the development of BH3120, a next-generation cancer…
Breakthrough liver cancer treatment: Merck’s new drug combo slashes disease progression risk by 34%
Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have…
EC approves PADCEV and KEYTRUDA combo for advanced urothelial cancer treatment
Astellas Pharma Inc. has announced a significant milestone in cancer treatment with the European Commission (EC’s) approval of…
Health Canada approves KEYTRUDA and Enfortumab Vedotin for advanced urothelial cancer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has…
Kineta Inc. resumes VISTA-101 trial enrollment for KVA12123 in advanced solid tumors
Kineta Inc. has announced the resumption of patient enrollment in its VISTA-101 Phase 1/2 clinical trial, which is…
Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of…
Japan’s MHLW grants priority review for PADCEV and KEYTRUDA combo in urothelial cancer
In a significant development in the fight against urothelial cancer, Astellas Pharma Inc. announced that Japan’s Ministry of…